INCLUSION CRITERIA:
Patients must have histopathological documentation of prostate cancer confirmed in the Pathology Department of the Clinical Center at the National Institutes of Health or the National Naval Medical Center prior to starting this study. Patients whose pathology specimens are no longer available may be enrolled in the trial, if the patient has a clinical course consistent with prostate cancer and pathologic documentation of the diagnosis.
Patients must have metastatic progressive androgen-independent prostate cancer (progressive prostate cancer while continuing to receive hormonal ablation, such as that of an LHRH agonist) documented prior to entry. Progression must be documented by at least one of the following parameters:
1. Two consecutively rising PSA levels, separated by at least one week, with at least one measurement that is 50% above the nadir reached after the last therapeutic maneuver (as long as the measurement is 5 ng/ml or greater); and/or,
2. At least one new metastatic deposit on Tc-99 bone scintigraphy; and/or,
Progression of soft tissue metastases as measured by appropriate modalities (i.e., imaging, palpation):
1. Development of new area of malignant disease (measurable or non-measurable);
2. Measurable disease progression by RECIST criteria;
3. At least 4 weeks off of flutamide and 6 weeks off of bicultamide and nilutamide.
Patients who have not undergone surgical castration must continue treatment with an LHRH agonist. If for some reason the LHRH agonist has been discontinued prior to entry on the study, then it should be reinstituted and disease progression must be documented.
Patients must have a life expectancy of more than 3 months.
Patients must have a performance status of 0 to 2 according to the ECOG criteria.
Patients must have recovered from any acute toxicity related to prior therapy, including surgery.
Hematological eligibility parameters (within 2 weeks before starting therapy):
1. Granulocyte count greater than or equal to 1,500/mm(3)
2. Platelet count greater than or equal to 100,000/mm(3)
Biochemical eligibility parameters (within 2 weeks before starting therapy):
1. If the creatinine is greater than 1.5 mg/dl, a 24 hour urine collection must be obtained, and measured creatinine clearance must be at least 40 mL/min.
2. Hepatic function: Hepatic: Bilirubin less than 1.0 mg/dl, AST and ALT less than 2.5 times upper limit of normal. If the alkaline phosphatase is greater than 2.5 times the upper limit of normal, it must be fractionated and the hepatic alkaline phosphatase should be less than 2.5 times the upper limit of normal.
Hormonal profile for patients with prostate cancer
1. All patients who have not undergone surgical castration must have a serum testosterone under 50 ng/ml and continue on their GnRh agonist.
Patients must not have other active malignancies (within the past two years with the exception of non-melanoma skin cancers or carcinoma in situ of the bladder).
Patients with a history of unstable or newly diagnosed angina pectoris, recent myocardial infarction (within 6 months of enrollment), New York Heart Assoc. class II-IV congestive heart failure are not eligible.
Patients must be able to understand and sign an informed consent form.
Patients must be willing to travel from their home to the NIH for follow-up visits.
Patients must be greater than or equal to 18 years of age.
Must be able to ingest oral medications to be eligible.
EXCLUSION CRITERIA:
Patients with brain metastases will not be eligible.
Patients who have received strontium or samarium will not be eligible.
HIV-positive patients receiving combination anti-retroviral therapy will be excluded because of possible pharmacokinetic interactions with ketoconazole, docetaxel or other agents administered during the study. In fact, ketoconazole has been found to increase the toxic effects of several protease inhibitors by affecting CYP3A4 activity.
Patients on theophylline will be excluded.
Patients who are receiving cisapride will be excluded.
Patients who are receiving HMG-CoA inhibitors (lovastatin, atorvastatin, simvastatin, pravastatin and cerivastatin)
Patients currently taking known inhibitors and/or inducers of CYP3A4; patients taking known substrates of CYP3A4 will be evaluated by the primary investigator.
Patients who are receiving terfenadine, midazolam, triazolam, alprazolam, astemizole, loratadine, rifampin, isoniazid, dofetilide, pimozide, sirolimus or erythromycin will be excluded.
Because gastric acidity is necessary for the dissolution and absorption of ketoconazole, concomitant administration of drugs which decrease gastric acid output or increase gastric pH (e.g., antacids, cimetidine, ranitidine, antimuscarinics, omeprazole, and lansoprazole) may decrease absorption and thus will be prohibited.
Patients requiring warfarin will be excluded.
Warren Grant Magnuson Clinical Center (CC)